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Abstract
Aurora-A kinase has recently been shown to be deregulated in thyroid cancer cells and tissues.
Among the Aurora-A substrates identiﬁed, transforming acidic coiled-coil (TACC3), a member of
the TACC family, plays an important role in cell cycle progression and alterations of its expression
occur in different cancer tissues. In this study, we demonstrated the expression of the TACC3
gene in normal human thyroid cells (HTU5), and its modulation at both mRNA and protein levels
during cell cycle. Its expression was found, with respect to HTU5 cells, unchanged in cells derived
from a benign thyroid follicular tumor (HTU42), and signiﬁcantly reduced in cell lines derived from
follicular (FTC-133), papillary (B-CPAP), and anaplastic thyroid carcinomas (CAL-62 and 8305C).
Moreover, in 16 differentiated thyroid cancer tissues, TACC3 mRNA levels were found, with
respect to normal matched tissues, reduced by twofold in 56% of cases and increased by twofold
in 44% of cases. In the same tissues, a correlation between the expression of the TACC3 and
Aurora-A mRNAs was observed. TACC3 and Aurora-A interact in vivo in thyroid cells and both
proteins localized onto the mitotic structure of thyroid cells. Finally, TACC3 localization on spindle
microtubule was no more observed following the inhibition of Aurora kinase activity by VX-680. We
propose that Aurora-A and TACC3 interaction is important to control the mitotic spindle
organization required for proper chromosome segregation.
Endocrine-Related Cancer (2007) 14 827–837
Introduction
The transforming acidic coiled-coil (TACC) proteins
form an evolutionarily conserved family characterized
by the presence at their C-terminal end of a common
coiled-coil motif of w200 amino acids (Gergely 2002,
Still et al. 2004). In human, three members TACC1,
TACC2, and TACC3 have been identiﬁed and they are
involved in the progression of mitosis (Sadek et al.
2000, Gergely 2002). The relevance of TACC3
physiological function has been assessed by TACC3
knockout mice, which die during embryogenesis due to
a massive increase in apoptosis and overexpression of
the p53 target gene (Piekorz et al. 2002, Sadek et al.
2003). TACC3 protein is localized around the
centrosomes during mitosis where it forms complexes
with the microtubule-associated protein ch-TOG
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kinase (Gergely et al. 2000, Gergely 2002, Pascreau
et al. 2005). The latter belongs to the Aurora kinase
family which includes three members, namely Aur-
ora-A, Aurora-B, and Aurora-C (Bischoff & Plowman
1999, Carmena & Earnshaw 2003). Aurora-A is mainly
associated with centrosome in mitotic cells where it
interacts with and phosphorylates several substrates
including Eg5, TPX2, and the above-described TACC3
involved in spindle formation and stability (Bischoff &
Plowman 1999, Arlot-Bonnemains & Prigent 2002).
Aurora-A has been shown to be overexpressed in solid
tumor and its increase correlates with centrosome
ampliﬁcation (Bischoff & Plowman 1999). Indeed,
regulation of Aurora-A gene expression is critical for
centrosome functions and its up- or downregulation
leads to abnormal mitosis as well as to chromosome
segregation and cytokinesis defects (Bischoff & Plow-
man 1999). There is also evidence that TACC genes
expression is deregulated in different cancer tissues. In
fact, TACC1 gene was ﬁrst discovered as a gene
ampliﬁed in breast cancer and its overexpression
causes ﬁbroblast transformation, suggesting that its
ampliﬁcation contributes to cancer progression (Still et
al. 1999b). However, a reduction in its expression has
been documented in ovarian and breast cancer tissues
(Conte et al. 2002, Lauffart et al. 2005). Similarly,
TACC2 and TACC3 expression has been shown to be
reduced in several cancers (Chen et al. 2000, Lauffart
et al. 2003, Lauffart et al. 2005). Moreover, a number
of malignant tumors exhibit deletions or rearrange-
mentsof 4p16 and 8p11, the loci of TACC3 and TACC1
genes respectively (Sato et al. 1991, Still et al. 1999a).
Thyroid follicular cell-derived cancers are often
characterized by chromosomal instability and aneu-
ploidy (Shahedian et al. 2001, Ouyang et al. 2002).
They represent the most common endocrine malig-
nancy accounting for 1% of all new malignant diseases
(Sherman 2003). Although derived from the same cell
type, different thyroid neoplasms show speciﬁc
histological features, biological behavior, and degree
of differentiation, as a consequence of different genetic
alterations (Shahedian et al. 2001, Ouyang et al. 2002,
Nikiforova et al. 2003). The large majority offollicular
thyroid cancers are represented by the differentiated
papillary (B-CPAP) and follicular thyroid carcinomas
(FTCs) which, following dedifferentiation, are thought
to give rise to the aggressive anaplastic thyroid
carcinomas (Kinder 2003, Pasieka 2003).
We recently demonstrated an altered expression of
the Aurora-A gene in cell lines derived from different
histotypes of human thyroid tumors and in papillary
carcinoma tissues (Ulisse et al. 2006a). Since the
TACC3 protein represents a substrate of Aurora-A
kinase and, to the best of our knowledge, the
expression of the three TACC genes has never been
characterized in human thyroid tissues, we here
investigated the TACC3 expression, the cellular
localization in normal and transformed human thyr-
ocytes, and its interaction with Aurora-A. Finally, we
compared the expression level of TACC3 and Aurora-
A in thyroid cancer tissues.
Materials and methods
Cell lines and materials
Dulbecco’s modiﬁed Eagle’s medium, RPMI 1640
medium, ham’s medium nutrient mixture F-12, PBS,
fetal bovine serum (FBS), trypsin, EDTA, PBS,
L-glutamine 100! (200 mM), and penicillin/strepto-
mycin solution 100! were purchased from EuroClone
(Paignton-Devon, UK). The Aurora kinase inhibitor
VX-680 was obtained from KAWA Technology (San
Diego, CA, USA). Oligo(dT)12–18 primer, Trizol,
dNTP mix, and M-MLV reverse transcriptase were
purchased from Invitrogen. HotMaster Taq DNA
polymerase and Perfectprep Gel Cleanup Kit were
obtained from Eppendorf (Hamburg, Germany). All
primers were from PRIMM (Milan, Italy) and 100 bp
DNA ladder from New England BioLabs (Beverly,
MA, USA). Proteases inhibitors were purchased from
Roche, 4-(2-amino-ethyl) benzenesulfonyl ﬂuoride
hydrochloride, sodium orthovanadate, sodium pyro-
phosphate, the rabbit polyclonal anti-actin antibody,
the anti-b-tubulin, and the anti-g-tubulin monoclonal
antibodies were obtained from Sigma Chemical Co.
The goat (sc-5885) and the rabbit (sc-22773) poly-
clonal anti-TACC3 antibodies were purchased from
Santa Cruz (Cambridge, UK). The monoclonal anti-
Aurora-A antibody (clone 35C1) was obtained from
Abcam (Paris, France). All secondary antibodies
horseradish peroxidase conjugated were purchased
from Jackson Immuno Research Laboratories (Balti-
more, MD, USA).
Cell cultures and human thyroid tissues
The normal strain of human thyrocytes (HTU5) has
been cultured as previously described (Curcio et al.
1994, Perrella et al. 1997). These diploid and non-
tumorigeniccellsretaininculturethefunctionalfeature
of normal human thyrocytes, such as the ability to
express the major thyroid speciﬁc genes
(i.e. thyroglobulin and thyrotrophin (TSH) receptor)
andtoincreasecAMPlevelfollowingTSHstimulation.
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cultured as previously described (Ulisse et al. 2006a).
The cells were maintained in continuous monolayer
cultures at 37 8C and 5% CO2, expanded up to 70–80%
conﬂuence and then employed for the experiments as
described below. To investigate the effects of serum on
normal human thyrocyte proliferation and TACC3
expression, cells have been cultured for 4 days in the
presence of 5 or 0.3% FBS. Following 4 days in
medium containing low serum concentration, some of
the cells have been treated for additional 24 h in
medium containing 5% FBS. The cells have been then
processed to prepare total RNA and protein extracts.
Fragments of normal and tumoral thyroid tissues
were obtained from surgical specimens of 16 female
patients (age ranging from 36 to 76 years) of which 13
affected by papillary (papillary thyroid cancer, PTC,
six follicular and seven classical variants) and 3 by
FTC. Tissue samples were immediately frozen in
liquid nitrogen, stored at K80 8C, and then used to
prepare total RNA as described below.
RNA isolation and analysis
Total cellular RNA was extracted from the different
cell lines by the acid guanidinium thiocyanate–phenol–
chloroform method (Chomczynski & Sacchi 1987).
The same protocol was used to obtain total RNA from
normal and tumoral human thyroid tissues following
homogenization of the samples by Ultra-Turrax in
guanidinium thiocyanate. Five micrograms of total
RNA samples were reverse transcribed and the
obtained cDNAs used as a template for the quantitative
PCR ampliﬁcations of TACC3, Aurora-A, and b-actin
as internal control, using the following primers:
TACC3, forward 50-GAACTGGGGAAGATCATG
GA-30 (exon 10/11), reverse 50-CTCTTCGTTC
TTGCGGTAGC-30 (exon 12/13), amplicon 222 bp;
b-actin, forward 50-CAAGAGATGGCCACGGCT
GCT-30 (exon 3), reverse 50-TCCTTCTGCATCCT
GTCGGCA-30 (exon 4), amplicon 275 bp; Aurora A,
forward 50-CTGCATTTCAGGACCTGTTAAGG-30
(exon 1), reverse 50-AACGCGCTGGGAAGAATTT-
30 (exon 2), amplicon 150 bp. Controls for DNA
contamination were performed omitting the reverse
transcriptase. Real-time PCR assay was performed on
the LightCycler instrument (Roche Diagnostics),
employing the FastStart DNA Master SYBR Green I
Kit (Roche Applied Science) as previously described
(Ulisse et al. 2006b). The PCR products were analyzed
on 2% agarose gel and to determine the speciﬁcities of
ampliﬁed cDNAs, they were recovered from the gel,
puriﬁed with a gel cleanup kit, and subjected to
sequencing reactions in the presence of ﬂuorescent-
labeled nucleotides, then analyzed by ABI Prism 377
DNA sequencer (Perkin–Elmer, Boston, MA, USA).
All the obtained sequences corresponded to the
expected ones (data not shown). The crossing
points (Cp) for each reaction were determined and
calculation of data was performed with the DDCp
method using the LightCycler relative quantiﬁcation
software 1.0 (Roche Diagnostics). Expression of
the target genes in the tumoral thyroid tissues or
tumor-derived cell lines was normalized respectively,
against the expression found in the matched normal
tissues or the HTU5 cells, and reported as fold of
variation.
Western blot analysis
Cells protein extracts were obtained as previously
described (Ulisse et al. 2006a). Aliquots of 50 mg cell
or tissue extracts were resolved on a 12.5% SDS-
PAGE and transferred onto nitrocellulose membranes.
Incubations with anti-TACC3 (1:250) or anti-actin
(1:500) primary antibodies were performed in 2.5%
BSA in Tris buffer saline containing 0.05% of Tween
20 (TBST) at 4 8C overnight. Membranes were then
incubated with anti-goat (1:30 000) or anti-rabbit
(1:50 000) horseradish peroxidase-conjugated second-
ary antibodies. The western blots were revealed by
chemiluminescence using the Super Signal kit from
Pierce (Rockford, IL, USA).
Immunoﬂuorescence
The different cells lines were growth on glass cover
slips and treated as described (Ulisse et al. 2006a). The
cells were incubated for 1 h at room temperature with
the anti-TACC3 antibody (1:100) and/or anti-Aurora-
A (1:200) and anti-g-tubulin (1:200) or anti-b-tubulin
(1:200) antibodies. After washing, the cover slips were
incubated with a TRITC-conjugated anti-goat (1:100)
and FITC-conjugated anti-mouse (1:100) antibodies
for 1 h at room temperature and then mounted in
Vectashield (Vector Laboratories, Burlingame, CA,
USA) containing 1 mg/ml DAPI. Cover slips were
observed with a microscope Leica-DMRXA.
Co-immunoprecipitation of Aurora-A and TACC3
Five microliters of dried Sepharose protein-G (4 Fast-
ﬂow Sepharose, Amersham) were washed with 500 ml
lysis buffer and treated for 1 h at 4 8C with 500 ml lysis
buffer added with 5% BSA. After ﬁve washes, the
beads were incubated with 50 ml antibody anti-Aurora-
A or anti-TACC3 (sc-22773) for 2 h at 4 8C, and then
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incubated with a 2.5!10
6 cells extract for 2 h at 4 8C
on a wheel. The beads were then washed ﬁve times
with 500 ml lysis buffer. Bound proteins were eluted in
10 ml of 2X-Laemmli sample buffer and the proteins
were separated on a 12.5% SDS-PAGE and then
immunoblotted. The western blot analyses were
performed with the anti-TACC3 (1:250) and anti-
Aurora-A (1:200) antibodies.
Cell cycle analysis
The FTC-133 cells were cultured up to 70–80% of
conﬂuence and pulse-labeled with 30 mM BrdU for 2 h
at 37 8C. The cells were then rinsed with PBS and
collected by scraping with a rubber policeman in PBS.
Following centrifugation, the cells were ﬁxed in
ice-cold ethanol and FITC-PI stained as previously
described (Chang et al. 1999). All cell samples were
analyzed for DNA content (PI) and/or BrdU content
(FITC) using an EPICS Elike Flow cytometer
(Coultronics, Hialeah, FL, USA) equipped with an
argon laser (488 nm). Data analysis was carried out
using Multicycle software (Phoenix Flow Systems, San
Diego, CA, USA).
Statistical analysis
All the results are expressed as the meanGS.E.M.o fa t
least three independent experiments and values were
statistically compared using the Student’s t-test or the
two-tailed Wilcoxon rank sum test. Correlation
analysis between the fold of increase of TACC3 and
Aurora-A mRNAs was evaluated by the Pearson
correlation test using the SPSS software (SPSS Inc.,
Chicago, IL, USA). The results were determined to be
signiﬁcantly different if P values were lower than 0.05.
Results
Expression, cell cycle regulation, and
localization of TACC3 in normal human
thyrocytes (HTU5)
We ﬁrst evaluated the expression at the mRNA and
protein level of the TACC3 gene in HTU5 cells. We
demonstrated the presence of a speciﬁc TACC3
transcript in HTU5 cells. The omission of the reverse
transcriptase (negative control) prevented the forma-
tion of amplicons (Fig. 1A). Western blot analysis of
HTU5 cell protein extracts demonstrated the
presence of an immunoreactive band of w100 kDa,
which was completely abrogated when the anti-
TACC3 antibody was preincubated with the immune
peptide (Fig. 1B).
We next determined whether TACC3 expression was
cell cycle regulated in HTU5 cells. To this end, the cells
were cultured for 4 days in the presence offull medium
containing 5% FBS or in medium containing low serum
concentration (0.3%). Some of the latter were then
exposedtofreshmediumcontaining5%FBSfor24 h.In
theseconditions,wepreviouslyshown,bymeansofﬂow
cytometer analysis, that serum deprivation for 4 days
reduced the number of proliferating cells (SCG2/M-
phase) by more than 75%, while the exposure to fresh
medium containing 5% FBS restored the number of
proliferating cells to control level (Ulisse et al. 2006a).
AsshowninFig.1CandD,serumdeprivationinduceda
marked reduction in the expression of TACC3 gene, at
bothmRNAandprotein level.Theexposuretofreshfull
medium restored the expression of TACC3 gene at
control level (Fig. 1C and D). As TACC3 is cell cycle
regulated in thyrocytes, we next investigated the
subcellular localization of TACC3 protein by indirect
immunoﬂuorescence microscopy in the HTU5 cells. In
all interphasic cell lines tested, the TACC3 immunor-
eactivity was localized around the nuclei and decorated
part of the interphasic microtubules (Fig. 1E, upper
panel). In mitotic cells, TACC3 localized on the spindle
microtubules, whereb-tubulinwas alsolocalized,and in
thepericentrosomalmaterial(PCM)area.Nostainingfor
TACC3 protein was observed onto the centrosome, as
demonstrated by the double staining with g-tubulin
(Fig. 1E, middle and lower panels).
Interaction of TACC3 with Aurora-A in
thyroid cells
Since Aurora-A has been reported to interact with
TACC3 in other cellular systems, we analyzed their
interaction in thyroid cells. To this end, the FTC-
derived cell line, the FTC-133 was employed, since
these cells express a high level of Aurora-A (Ulisse
et al. 2006a) and, as described above, a relative high
amount of TACC3. As in HTU5 cells, TACC3
co-localized with b-tubulin, but not g-tubulin on the
spindle microtubules, and was observed on the PCM
(Fig. 2A, upper and middle panels). As expected,
Aurora-A was found to localize on the centrosome and
the microtubules of the spindle poles (Fig. 2A, lower
panel). TACC3 co-localized with Aurora-A solely on
the PCM and the microtubules of the spindle poles. We
thus investigated the interaction between TACC3 and
Aurora-A by immunoprecipitating Aurora-A or
TACC3 from FTC-133 cell extracts. The presence of
TACC3 in the Aurora-A immunoprecipitate as well
as that of Aurora-A in the TACC3 immunoprecipitate,
demonstratedthatAurora-AandTACC3interact,either
directly or indirectly, in human thyroid cells (Fig. 2B).
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from HTU5 cells were used to prepare cDNA in the presence or absence of the reverse transcriptase. The cDNAs were ampliﬁed by
quantitative RT-PCR using speciﬁc primers for TACC3 and actin as described in Materials and methods. (B) Fifty micrograms of cell
protein extracts have been analyzed by western blot with an anti-TACC3 antibody (diluted 1/250) preincubated or not with the
immunogenic peptide (upper panel) and anti-actin antibody (1/500; lower panel). (C and D) HTU5 cells have been treated for 4 days
in the presence of 5% (C) or 0.3% (SF) FBS, some of the latter were then cultured for additional 24 h in media containing 5% FBS.
Quantitative RT-PCR (C) and western blot (D) analyses for TACC3 were performed on cell extracts as described in Materials and
methods. Data reported are representative of one out of three experiments. (E) Interphasic (upper panel) and mitotic (middle and
lower panels) HTU5 cells were stained for TACC3 and b-tubulin (upper and middle panels) as a marker of microtubules or g-tubulin
(lower panel) as a marker for centrosome as described in Material and methods. Scale bar, 10 mm.
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some maturation, and TACC3 localization
In the attempt to elucidate the functional role of
Aurora-A and TACC3 interaction, the effects of FTC-
133 treatment with the Aurora kinase inhibitor VX-680
were studied. In particular, FTC-133 cells were treated
with VX-680 at 500 nM, a concentration previously
shown on different cell types to elicit maximal
response (Harrington et al. 2004). Analysis of cell
DNA content after 24-h treatment, by ﬂow cytometer
analysis, showed the accumulation of cells with R4N
DNA content (Fig. 3A). Cell treatment with VX-680
did not affect neither the levels of TACC3 or Aurora-A
proteins (Fig. 3B). Immunoﬂuorescence experiments
demonstrated that 84.1% of VX-680-treated cells have
more than two centrosomes compared with 4% in
control cells (Fig. 3C). In the latter, all mitotic cells
showed the presence of aberrant spindles characterized
by shorter microtubules, or no spindle. In VX-680-
treated cells, Aurora-A still present on the centro-
somes, while TACC3 was missing on the spindle
microtubules (Fig. 3C).
TACC3 gene expression in transformed human
thyrocytes
The above observations lead us to investigate the
expression level of TACC3 gene in different human cell
lines derived from benign follicular adenoma (HTU42),
follicular (FTC-133), papillary (B-CPAP), and anaplastic
(8305C and CAL-62) thyroid carcinomas. Quantitative
RT-PCR analysis revealed that TACC3 mRNA levels
weresimilarintheHTU42 andHTU5cells, while alower
Figure 2 TACC3 and Aurora A kinase interaction and localization in FTC-133 thyroid cells. (A) Mitotic FTC-133 cells were stained
for TACC3 and b-tubulin (upper panel) or g-tubulin (middle panel) or Aurora-A (lower panel) as described in Materials and
methods. Scale bar, 10 mm. (B and C) Aurora-A or TACC3 were immunoprecipitated from FTC-133 cell extracts using either the
anti-Aurora-A monoclonal antibody (B) or the anti-TACC3 polyclonal antibody (C). Aurora-A and TACC3 were then immunodetected
with the anti-Aurora-A monoclonal antibody (upper panel) and the polyclonal anti-TACC3 antibody (lower panel) as described in
Materials and methods.
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lines(Fig.4A).Inparticular,theTACC3mRNAlevelwas
reduced in the FTC-133 (0.72G0.06; P!0.01), the
B-CPAP (0.64G0.01; P!0.01), the 8305C (0.39G
0.04; P!0.01), and the CAL-62 (0.33G0.03; P!0.01)
cell lines. Likewise, with respect to the HTU5 cells, the
TACC3 protein was found signiﬁcantly reduced in the
FTC-133 (0.85G0.05; P!0.05), B-CPAP (0.53G0.05;
P!0.01), 8305C (0.35G0.13; P!0.01), and CAL-62
(0.17G0.08; P!0.01), but similar in the HTU42 cells
(0.98G0.29; Fig. 4Ba n dC ) .
Expression of TACC3 and Aurora-A in normal
and differentiated thyroid carcinoma tissues
The levels of the TACC3 mRNA in PTC and FTC
carcinoma tissues were compared with those of the
matched normal thyroid by means of quantitative
RT-PCR. The results are shown in Fig. 5A. TACC3
mRNA levels were lower in 7 out of 13 PTCs and 2 out
of 3 FTCs, but higher in 6 PTCs and 1 FTC than in the
normal tissue. Altogether, TACC3 mRNA levels were
reduced in 56% of the differentiated thyroid cancers
Figure 3 Effects of Aurora kinase inhibition by VX-680 on FTC-133 cell ploidy, spindle formation and TACC3 subcellular localization.
(A) FTC-133 cells were incubated for 24 h with 500 nM VX-680 or DMSO used as vehicle (control) and pulse labeled with BrdU for
2 h. The cells were then ﬁxed and analyzed by ﬂow as described in Materials and methods. (B) Fifty micrograms of cell protein
extracts from control and VX-680-treated cells were analyzed by western blot with an anti-TACC3 antibody (diluted 1/250), anti-
Aurora-A (diluted 1:500), or anti-actin antibody (1/500). (C) Subcellular localization of Aurora-A and TACC3 in control and VX-680-
treated FTC-133 mitotic cells. Fixed cells were stained for TACC3 and b-tubulin or Aurora-A and b-tubulin as described in Materials
and methods. Scale bar, 10 mm.
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DTC (1.96G0.35; P!0.05) when compared with their
normal matched tissues. Since TACC3 and Aurora-A
interactinthyroidcells,theexpressionofAurora-Awas
determinedinthesametissues.Theresultsareshownin
Fig. 5B. Quantitative RT-PCR revealed that Aurora-A
was upregulated in 5 out of 13 PTCs (2.75G0.44;
P!0.01). Downregulation of Aurora-A was noted in
ﬁve PTCs (0.51G0.13; P!0.01) and all three FTCs
(0.41G0.03; P!0.01).
Using a linear regression analysis, we evidenced a
signiﬁcant correlation (rZ0.717; P!0.01) between
the variations of TACC3 and Aurora-A mRNAs in
thyroid cancer tissues (Fig. 5C). We ﬁnally attempted
to correlate the variation of TACC3 and Aurora-A
expression in thyroid cancer tissues with the clinical
and histological parameters, including patient’s age,
stage, tumor size, and histology. No correlation could
be found with any of the parameters analyzed.
Discussion
As our knowledge about the molecular process
controlling cell division is growing, an increasing
number ofproteins are now suspected to play a relevant
role in the genetic instability, an hallmark of solid
cancers progression. Thyroid follicular neoplasms are
often characterized by aneuploidy (Shahedian et al.
2001, Ouyang et al. 2002). In this context, we recently
demonstrated that the three members of the Aurora
kinase family, Aurora-A, Aurora-B, and Aurora-C,
involved in the regulation of multiple aspects of
chromosome segregation and cytokinesis, are over-
expressed in malignant thyroid tumor-derived cell lines
and tissues (Ulisse et al. 2006a). In particular, the
alteration in Aurora-A gene expression may help to
shed some light on the molecular mechanisms involved
in the genetic instability of thyroid cancers. In fact, the
overexpression of Aurora-A in different human cell
lines has been shown to induce centrosome ampliﬁ-
cation and to potentiate the oncogenic action of Ras. In
human thyrocytes, Ras participates in transformation
and chromosome instability (Bischoff & Plowman
1999, Tatsuka et al. 2005). Furthermore, it has been
documented that p53 is a substrate of Aurora-A and its
phosphorylationon Ser215 leadstothe inhibition ofthe
p53 transactivating action on several genes (Liu et al.
2004). Thus, alterations in the crosstalk between
Aurora kinase A and p53 could be relevant in thyroid
tumor progression by compromising the ﬁdelity of
chromosome segregation (Parry et al. 1998, Shahedian
et al. 2001).
In order to get more insight about the molecular
mechanism of thyroid cancer progression, we have
here characterized, in normal and tumoral human
thyrocytes and tissues, the expression of TACC3 gene
which encodes for a protein substrate of Aurora-A.
TACC proteins belong to a conserved family of
centrosome and microtubule-associated proteins
whose functions are not clearly understood. Never-
theless, it is well established that these proteins are all
involved in the regulation of the mitotic phase of the
cell cycle (Gergely 2002). Clues about their functions
Figure 4 Expression of TACC3 gene in normal human
thyrocytes (HTU5) and cell lines derived from thyroid benign
follicular adenoma (HTU42) and from papillary (B-CPAP),
follicular (FTC-133), and anaplastic (8305C and CAL-62)
thyroid carcinomas. (A) Quantitative RT-PCR analysis of
TACC3 mRNA levels. Aliquots of 5 mg RNA were analyzed by
RT-PCR. Messenger RNA variations were relative to the
TACC3/actin ratio observed in HTU5 cells. Data reported
represent the meanGS.E.M. of three independent experiments.
Statisticalsigniﬁcance of datawas assessedbyStudent’s t-test.
*P!0.01, **P!0.05. (B and C) Western blot analysis of TACC3
protein in the different cell lines as described above. Fifty
micrograms of the cell protein extracts were analyzed for
TACC3 and actin contents by immunoblotting (B). TACC3
variations (C) were relative to the TACC3/actin ratio observedin
HTU5 cells. Data reported represent the meanGS.E.M. of three
independent experiments. Statistical signiﬁcance of data was
assessed by Student’s t-test. *P!0.01, **P!0.05.
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proteins are likely important in M-phase entry since
they regulate both spindle assembly and mRNA
translation (Pascreau et al. 2005, Peset et al. 2005).
The three human TACC proteins are also suspected to
play a role in oncogenesis. Aberrations of TACC genes
have been associated with various cancers (Still et al.
1999a, Conte et al. 2002, Line et al. 2002, Lauffart
et al. 2005). In particular, TACC3 have been found
overexpressed in various cancer cell lines (Still et al.
1999a) but, in contrast, lost in 67% ovarian tumors
(Lauffart et al. 2005).
Up to now, the expression and functions of TACC3
in human thyrocytes have not been documented. In the
present report, we demonstrate that TACC3 gene is
expressed in normal human thyrocytes. Its expression
is likely cell cycle regulated, since it is downregulated
in serum-deprived cultured cells and restored after
serum addition. Our immunoﬂuorescence results
showing that TACC3 is localized along the spindle
microtubules in mitotic cells are in favor of a cell
cycle-regulated expression of the TACC3 protein in
thyrocytes.
In Xenopus and Drosophila, Aurora-A has been
shown to interact with the human TACC3 orthologues,
maskin, and D-TACC respectively (Giet et al. 2002,
Pascreau et al. 2005). In human thyroid cells, Aurora-A
and TACC3 co-localized at the spindle pole, where
they may have a role in microtubules growth and
stability, as suggested in Drosophila (Raff 2002).
Inhibition of Aurora-A by VX-680 in FTC-133 cells
which lead to abnormal spindle formation charac-
terized by shorter microtubules, delocalized TACC3
from the spindle microtubules. This suggests that the
kinase activity of Aurora-A is needed for the
localization of TACC3 on the spindle. However,
even in the presence of VX-680, Aurora-A and
TACC3 co-immunoprecipitated (data not shown).
The apparent discrepancy between the IP and the IF
observation in VX-680-treated cells may be due to the
fact that the VX-680 is a reversible inhibitor and that
reassociation of the two proteins may take place during
the cell protein extraction procedure used for the
co-immunoprecipitation experiments. Nevertheless,
these observations suggest that Aurora-A activity is,
directly or indirectly, required for TACC3 localization
on the spindle microtubule. This is in agreement with
recent observations in Xenopus laevis egg extracts
showing that Aurora-A phosphorylation of TACC3/
maskin is required for centrosome-dependent micro-
tubule assembly in mitosis (Kinoshita et al. 2005).
Opposite variations of TACC expression have been
reported in various cancers. Upregulation of TACC3
expression has been observed during the transition of
breast cancer from in situ preinvasive ductal carcinoma
to invasive ductal carcinoma, and in multiple myeloma
(Still et al. 1999a, Ma et al. 2003). In contrast, a high
proportion of human breast and ovarian cancer tissues
shows a downregulation of TACC1 and TACC3
expression (Conte et al. 2002, 2003, Lauffart et al.
2005). In this work, we show that TACC3 expression
was signiﬁcantly downregulated in different thyroid
carcinoma-derived cell lines, but not in a cell line
derived from a benign follicular thyroid tumor.
In particular, the reduction of TACC3 expression was
more important in the two cell lines derived from the
highly aggressive human anaplastic thyroid carci-
nomas (8305C and CAL-62). In contrast, in samples
of differentiated thyroid cancer (DTC) tissues, both up-
and downregulation were observed. Fifty-six percent
of DTC showed a signiﬁcant reduction in TACC3 gene
expression while TACC3 expression was found to be
signiﬁcantly upregulated in 44%. Taken all together,
Figure 5 TACC3 and Aurora-A kinase expression in matched
cancer and normal thyroid tissues. (A and B) Quantitative
RT-PCR analysis of TACC3 (A) and Aurora-A kinase (B) mRNA
levels in 13 papillary (PTC) and 3 follicular (FTC) thyroid cancer
tissues compared with normal matched tissues obtained from
the same patients. mRNA variations were relative to the
TACC3/actinor AuroraA/actin ratios observedin normalthyroid
tissues. The small bars represent the median values. (C)
Correlation analysis between the variations of TACC3 and
Aurora-A kinase mRNAs in the differentiated thyroid carci-
nomas (13 PTCs and 3 FTCs) analyzed.
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cells, TACC3 protein may function as both transform-
ing and tumor-suppressor factor, as demonstrated in
other cell types (Chen et al. 2000, Raff 2002).
Since TACC3 and Aurora-A are partners in thyroid
cells, the expression of Aurora-A was analyzed in the
same tissues. As for TACC3, both up- and down-
regulation of Aurora-A was observed. In a recent
study, performed on seven normal matched PTC
tissues, we reported an upregulation of Aurora-A in
ﬁve over seven normal matched PTC tissues (Ulisse
et al. 2006a). In the new series of thyroid cancer tissues
analyzed here, we found that Aurora-A expression was
upregulated in 5 out of 13 PTC tissues, unchanged in
three and downregulated in ﬁve PTC as well as in three
FTC tissues. Thus, we may speculate that, as
hypothesized for TACC3, either up- or downregulation
of Aurora-A may lead to a proliferative advantage for
thyroid cancer cells. This is not surprising since both
the up- and downregulation of its expression have been
reported to cause abnormal mitosis with defects in
chromosome segregation and cytokinesis (Bischoff &
Plowman 1999). Interestingly, we found that the
expression of TACC3 and Aurora-A in thyroid cancer
varied together. This observation corroborates similar
ﬁndings reported in breast cancer tissues (Conte et al.
2003) and suggests common molecular mechanism(s)
regulating their expression. In breast cancers, increased
expressions of TACC3 and Aurora-A mRNAs have
been linked with cancer progression and high-grade
tumors (Ma et al. 2003). In contrast, in the series of
thyroid cancers analyzed here, no correlation was
found between the expression of either Aurora-A or
TACC3, and clinical or histological parameters
(including patient’s age, tumor stage, size, or his-
tology). Nevertheless, this needs to be conﬁrmed on a
larger number of cases.
In conclusion, we demonstrated that TACC3 gene is
expressed in human thyroid cells in a cell cycle-related
manner. In human thyrocytes, TACC3 interacted with
Aurora-A, whose activity is required for its localization
on the spindle microtubules. We also observed that
TACC3 and Aurora-A expression varied together in
thyroid cancer tissues. Altogether, this suggests that
these proteins may serve similar cellular functions and
that deregulation of one or both gene expression may
participate to thyroid cancer aneuploidy.
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